Skip to main content

Articles

Page 2 of 26

  1. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Yang Liu, Li-Li Lu, Duo Wen, Dong-Li Liu, Li-Li Dong, Dong-Mei Gao, Xin-Yu Bian, Jian Zhou, Jia Fan and Wei-Zhong Wu

    Citation: Journal of Hematology & Oncology 2020 13:44

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:12

  2. The novel coronavirus (2019-nCoV) is an emerging causative agent that was first described in late December 2019 and causes a severe respiratory infection in humans. Notably, many of affected patients of COVID-...

    Authors: Peiwei Chai, Jie Yu, Shengfang Ge, Renbing Jia and Xianqun Fan

    Citation: Journal of Hematology & Oncology 2020 13:43

    Content type: Letter to the Editor

    Published on:

  3. Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T cell (CAR-T) ther...

    Authors: Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang, Xin Li, Jing Chen, Xianmin Song, Hongmei Jing, Yuhua Li, Siguo Hao…

    Citation: Journal of Hematology & Oncology 2020 13:42

    Content type: Rapid communication

    Published on:

  4. Aberrant activation of DNA damage response (DDR) is a major cause of chemoresistance in colorectal cancer (CRC). CHK1 is upregulated in CRC and contributes to therapeutic resistance. We investigated the upstre...

    Authors: Xinfang Yu, Wei Li, Haidan Liu, Qipan Deng, Xu Wang, Hui Hu, Zijun Y. Xu-Monette, Wei Xiong, Zhongxin Lu, Ken H. Young, Wei Wang and Yong Li

    Citation: Journal of Hematology & Oncology 2020 13:40

    Content type: Research

    Published on:

  5. Ovarian cancer is one of the most lethal gynecologic malignancies reported throughout the world. The initial, standard-of-care, adjuvant chemotherapy in epithelial ovarian cancer is usually a platinum drug, su...

    Authors: Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak and Aneta Rogalska

    Citation: Journal of Hematology & Oncology 2020 13:39

    Content type: Review

    Published on:

  6. Rituximab in combination with chemotherapy has shown efficacy in patients with diffuse large B-cell lymphoma (DLBCL) for more than 15 years. HLX01 was developed as the rituximab biosimilar following a stepwise...

    Authors: Yuankai Shi, Yongping Song, Yan Qin, Qingyuan Zhang, Xiaohong Han, Xiaonan Hong, Dong Wang, Wei Li, Yang Zhang, Jifeng Feng, Jianmin Yang, Huilai Zhang, Chuan Jin, Yu Yang, Jianda Hu, Zhao Wang…

    Citation: Journal of Hematology & Oncology 2020 13:38

    Content type: Letter to the Editor

    Published on:

  7. Rearranged during transfection (RET) has been proven to be a tumorigenic target in non-small cell lung cancers (NSCLCs). In RET-rearranged NSCLCs, molecular features and their impact on prognosis were not well il...

    Authors: Chang Lu, Xiao-Rong Dong, Jun Zhao, Xu-Chao Zhang, Hua-Jun Chen, Qing Zhou, Hai-Yan Tu, Xing-Hao Ai, Xiao-Feng Chen, Gai-Li An, Jun Bai, Jin-Lu Shan, Yi-Na Wang, Shuan-Ying Yang, Xiang Liu, Wu Zhuang…

    Citation: Journal of Hematology & Oncology 2020 13:37

    Content type: Research

    Published on:

  8. Current acute myeloid leukemia (AML) therapy fails to eliminate quiescent leukemic blasts in the bone marrow, leading to about 50% of patient relapse by increasing AML burden in the bone marrow, blood, and ext...

    Authors: Victor Pallarès, Ugutz Unzueta, Aïda Falgàs, Laura Sánchez-García, Naroa Serna, Alberto Gallardo, Gordon A. Morris, Lorena Alba-Castellón, Patricia Álamo, Jorge Sierra, Antonio Villaverde, Esther Vázquez, Isolda Casanova and Ramon Mangues

    Citation: Journal of Hematology & Oncology 2020 13:36

    Content type: Research

    Published on:

  9. N6-methyladenosine (m6A) is a well-known post-transcriptional modification that is the most common type of methylation in eukaryotic mRNAs. The regulation of m6A is dynamic and reversible, which is erected by m6A...

    Authors: Yanchun Zhao, Yuanfei Shi, Huafei Shen and Wanzhuo Xie

    Citation: Journal of Hematology & Oncology 2020 13:35

    Content type: Review

    Published on:

  10. Abl interactor 1 (Abi1) is a downstream target of Abl tyrosine kinases and a component of the WAVE regulatory complex (WRC) that plays an important role in regulating actin cytoskeleton remodeling and membrane...

    Authors: James Faulkner, Peixin Jiang, Delaney Farris, Ryan Walker and Zonghan Dai

    Citation: Journal of Hematology & Oncology 2020 13:34

    Content type: Research

    Published on:

  11. Soft-tissue sarcomas represent a heterogeneous group of diseases with distinct genetic and clinical features accounting for up to 1% of cancer in adults and 15% of cancer in children. Epithelioid sarcoma is an...

    Authors: Antoine Italiano

    Citation: Journal of Hematology & Oncology 2020 13:33

    Content type: Editorial

    Published on:

  12. In the search for novel antibody-drug conjugates (ADCs) with therapeutic potential, it is imperative to identify novel targets to direct the antibody moiety. CD13 seems an attractive ADC target as it shows a d...

    Authors: Juan Manuel Domínguez, Gema Pérez-Chacón, María José Guillén, María José Muñoz-Alonso, Beatriz Somovilla-Crespo, Danay Cibrián, Bárbara Acosta-Iborra, Magdalena Adrados, Cecilia Muñoz-Calleja, Carmen Cuevas, Francisco Sánchez-Madrid, Pablo Avilés and Juan M. Zapata

    Citation: Journal of Hematology & Oncology 2020 13:32

    Content type: Rapid communication

    Published on:

  13. Hematopoietic stem cell (HSC) aging, which is accompanied by reduced self-renewal ability, impaired homing, myeloid-biased differentiation, and other defects in hematopoietic reconstitution function, is a hot ...

    Authors: Xia Li, Xiangjun Zeng, Yulin Xu, Binsheng Wang, Yanmin Zhao, Xiaoyu Lai, Pengxu Qian and He Huang

    Citation: Journal of Hematology & Oncology 2020 13:31

    Content type: Review

    Published on:

  14. Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-m...

    Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

    Citation: Journal of Hematology & Oncology 2020 13:30

    Content type: Rapid communication

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:53

  15. Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...

    Authors: Chongxian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li and Lei Zheng

    Citation: Journal of Hematology & Oncology 2020 13:29

    Content type: Review

    Published on:

  16. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy is still not available for acute myeloid leukemia (AML). One major issu...

    Authors: Cunte Chen, Chaofeng Liang, Shunqing Wang, Chi Leong Chio, Yuping Zhang, Chengwu Zeng, Shaohua Chen, Caixia Wang and Yangqiu Li

    Citation: Journal of Hematology & Oncology 2020 13:28

    Content type: Letter to the Editor

    Published on:

  17. Previous reports suggest a benefit associated with haploidentical donor transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain contexts, and the choice of optimal candidates...

    Authors: Ying-Jun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei-Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu and Xiao-Jun Huang

    Citation: Journal of Hematology & Oncology 2020 13:27

    Content type: Research

    Published on:

  18. Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibiti...

    Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma

    Citation: Journal of Hematology & Oncology 2020 13:26

    Content type: Review

    Published on:

  19. During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cells develop multipl...

    Authors: Ming Yi, Linping Xu, Ying Jiao, Suxia Luo, Anping Li and Kongming Wu

    Citation: Journal of Hematology & Oncology 2020 13:25

    Content type: Review

    Published on:

  20. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to tumor progression. However, the mechanisms regulating expression of glycolytic genes in neuroblastoma (NB), the most common extra...

    Authors: Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng and Qiangsong Tong

    Citation: Journal of Hematology & Oncology 2020 13:24

    Content type: Research

    Published on:

  21. The original article [1] contains an error in Fig. 5b whereby two panels have been mistakenly duplicated. The correct version of Fig. 5b can be viewed ahead alongside the rest of Fig. 5.

    Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie

    Citation: Journal of Hematology & Oncology 2020 13:23

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:17

  22. Methylation of RNA and DNA, notably in the forms of N6-methyladenosine (m6A) and 5-methylcytosine (5mC) respectively, plays crucial roles in diverse biological processes. Currently, there is a lack of knowledge r...

    Authors: Yu-Tong Chen, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, Wen-Fei Li, Zi-Xian Wang and Yu-Pei Chen

    Citation: Journal of Hematology & Oncology 2020 13:22

    Content type: Letter to the Editor

    Published on:

  23. Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to c...

    Authors: Dok Hyun Yoon, Junning Cao, Tsai-Yun Chen, Koji Izutsu, Seok Jin Kim, Yok Lam Kwong, Tong Yu Lin, Lim Soon Thye, Bing Xu, Deok Hwan Yang and Won Seog Kim

    Citation: Journal of Hematology & Oncology 2020 13:21

    Content type: Review

    Published on:

  24. Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells. VM has two distinct types, namely tubular type and patterned matr...

    Authors: Qingxi Luo, Jun Wang, Wenyuan Zhao, Zhenzi Peng, Xianyu Liu, Bin Li, Heng Zhang, Bin Shan, Chunfang Zhang and Chaojun Duan

    Citation: Journal of Hematology & Oncology 2020 13:19

    Content type: Review

    Published on:

  25. Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of haploidentical donor (HID) transplant for refractory acute leukemia need to be further explored. In this study, we compared the outcome...

    Authors: Sijian Yu, Fen Huang, Zhiping Fan, Li Xuan, Danian Nie, Yajing Xu, Ting Yang, Shunqing Wang, Zujun Jiang, Na Xu, Ren Lin, Jieyu Ye, Dongjun Lin, Jing Sun, Xiaojun Huang, Yu Wang…

    Citation: Journal of Hematology & Oncology 2020 13:18

    Content type: Short report

    Published on:

  26. Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with highly invasive ability and metastatic nature to the lymph nodes. Long non-coding RNAs (lncRNAs) have been widely explor...

    Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie

    Citation: Journal of Hematology & Oncology 2020 13:17

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:23

  27. NoncoRNA (http://​www.​ncdtcdb.​cn:​8080/​NoncoRNA/​) is a manually curated database of experimentally supported non-coding RNAs (ncRNAs) and drug target associations that aim to potentially provide a high-quality data...

    Authors: Lulu Li, Pengfei Wu, Zhenyu Wang, Xiangqi Meng, Caijun Zha, Ziwei Li, Tengfei Qi, Yangong Zhang, Bo Han, Shupeng Li, Chuanlu Jiang, Zheng Zhao and Jinquan Cai

    Citation: Journal of Hematology & Oncology 2020 13:15

    Content type: Letter to the Editor

    Published on:

  28. Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast ca...

    Authors: F. Coussy, R. El Botty, M. Lavigne, C. Gu, L. Fuhrmann, A. Briaux, L. de Koning, A. Dahmani, E. Montaudon, L. Morisset, L. Huguet, L. Sourd, P. Painsec, S. Chateau-Joubert, T. Larcher, S. Vacher…

    Citation: Journal of Hematology & Oncology 2020 13:13

    Content type: Short report

    Published on:

  29. MicroRNA-612 (miR-612) has been proven to suppress EMT, stemness, and tumor metastasis of hepatocellular carcinoma (HCC) via PI3K/AKT2 and Sp1/Nanog signaling. However, its biological roles on HCC progression ...

    Authors: Yang Liu, Li-Li Lu, Duo Wen, Dong-Li Liu, Li-Li Dong, Dong-Mei Gao, Xin-Yu Bian, Jian Zhou, Jia Fan and Wei-Zhong Wu

    Citation: Journal of Hematology & Oncology 2020 13:12

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:44

  30. Aberrant AKT activation contributes to cancer stem cell (CSC) traits in hepatocellular carcinoma (HCC). We previously reported that CD73 activated AKT signaling via the Rap1/P110β cascade. Here, we further exp...

    Authors: Xiao-Lu Ma, Bo Hu, Wei-Guo Tang, Su-Hong Xie, Ning Ren, Lin Guo and Ren-Quan Lu

    Citation: Journal of Hematology & Oncology 2020 13:11

    Content type: Research

    Published on:

  31. Lung cancer (LC) is the leading cause of cancer-related death worldwide due to its late diagnosis and poor outcomes. As has been found for other types of tumors, there is increasing evidence that myeloid-deriv...

    Authors: Zhenzhen Yang, Jiacheng Guo, Lanling Weng, Wenxue Tang, Shuiling Jin and Wang Ma

    Citation: Journal of Hematology & Oncology 2020 13:10

    Content type: Review

    Published on:

  32. PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably u...

    Authors: Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang and Beihua Kong

    Citation: Journal of Hematology & Oncology 2020 13:9

    Content type: Research

    Published on:

  33. Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) inclu...

    Authors: Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker…

    Citation: Journal of Hematology & Oncology 2020 13:8

    Content type: Research

    Published on:

  34. Long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to non-small-cell lung cancer (NSCLC) metastasis remain poorly understood. Our previous and oth...

    Authors: Zhenyao Chen, Xin Chen, Binbin Lu, Yu Gu, Qinnan Chen, Tianyao Lei, Fengqi Nie, Jingyao Gu, Jiali Huang, Chenchen Wei, Ming Sun and Zhaoxia Wang

    Citation: Journal of Hematology & Oncology 2020 13:7

    Content type: Research

    Published on:

  35. BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, ...

    Authors: Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu and Yuankai Shi

    Citation: Journal of Hematology & Oncology 2020 13:6

    Content type: Rapid communication

    Published on:

  36. Long non-coding RNAs (lncRNAs) possess significant regulatory functions in multiple biological and pathological processes, especially in cancer. Dysregulated lncRNAs in hepatocellular carcinoma (HCC) and their...

    Authors: Xueliang Zuo, Zhiqiang Chen, Wen Gao, Yao Zhang, Jinguo Wang, Junfeng Wang, Ming Cao, Juan Cai, Jindao Wu and Xuehao Wang

    Citation: Journal of Hematology & Oncology 2020 13:5

    Content type: Research

    Published on:

  37. The propensity of the activated neutrophils to form extracellular traps (NETs) is demonstrated in multiple inflammatory conditions. In this study, we investigated the roles of NETs in metastasis of hepatocellu...

    Authors: Lu-Yu Yang, Qin Luo, Lu Lu, Wen-Wei Zhu, Hao-Ting Sun, Ran Wei, Zhi-Fei Lin, Xiang-Yu Wang, Chao-Qun Wang, Ming Lu, Hu-Liang Jia, Jin-Hong Chen, Ju-Bo Zhang and Lun-Xiu Qin

    Citation: Journal of Hematology & Oncology 2020 13:3

    Content type: Research

    Published on:

  38. Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms...

    Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang…

    Citation: Journal of Hematology & Oncology 2020 13:2

    Content type: Research

    Published on:

  39. Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FD...

    Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica…

    Citation: Journal of Hematology & Oncology 2020 13:1

    Content type: Letter to the Editor

    Published on:

  40. In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy,...

    Authors: Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2019 12:145

    Content type: Research

    Published on:

  41. Signaling pathways critical for embryonic development re-emerge in adult pancreas during tumorigenesis. Aspartate β-hydroxylase (ASPH) drives embryonic cell motility/invasion in pancreatic development/differen...

    Authors: Kosuke Ogawa, Qiushi Lin, Le Li, Xuewei Bai, Xuesong Chen, Hua Chen, Rui Kong, Yongwei Wang, Hong Zhu, Fuliang He, Qinggang Xu, Lianxin Liu, Min Li, Songhua Zhang, Katsuya Nagaoka, Rolf Carlson…

    Citation: Journal of Hematology & Oncology 2019 12:144

    Content type: Research

    Published on:

  42. The original article [1] contains several errors.

    Authors: Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu and Libin Wei

    Citation: Journal of Hematology & Oncology 2019 12:143

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2015 8:41

  43. Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understandin...

    Authors: Han Fan, Utkan Demirci and Pu Chen

    Citation: Journal of Hematology & Oncology 2019 12:142

    Content type: Review

    Published on:

  44. Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malig...

    Authors: Lauren C. Fleischer, H. Trent Spencer and Sunil S. Raikar

    Citation: Journal of Hematology & Oncology 2019 12:141

    Content type: Review

    Published on:

  45. Statistical data on the incidence, mortality, and burden of breast cancer and the relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer incidence, deaths, and disability-adju...

    Authors: Na Li, Yujiao Deng, Linghui Zhou, Tian Tian, Si Yang, Ying Wu, Yi Zheng, Zhen Zhai, Qian Hao, Dingli Song, Dai Zhang, Huafeng Kang and Zhijun Dai

    Citation: Journal of Hematology & Oncology 2019 12:140

    Content type: Research

    Published on:

  46. Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies that target hematological canc...

    Authors: Qinghua He, Xianhan Jiang, Xinke Zhou and Jinsheng Weng

    Citation: Journal of Hematology & Oncology 2019 12:139

    Content type: Review

    Published on:

Annual Journal Metrics

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here